Jeffrey Allebach

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

B. Douglas Smith, Mark J. Levis, Miloslav Beran et al. · Blood · 2004 · 622 citations

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse et al. · Blood · 2002 · 469 citations

FLT3/ITD Mutation Signaling Includes Suppression of SHP-1

Peili Chen, Mark J. Levis, Patrick A. Brown et al. · Journal of Biological Chemistry · 2004 · 41 citations · Full text